Trinity, FL

Bayside Clinical Research

Hypertriglyceridemia

Ulcer

Colitis

Ulcerative Colitis

Olezarsen

ISIS 678354

SPH3127

Ionis Pharmaceuticals

Shanghai Pharma Biotherapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Bayside Clinical Research | Trinity, FL

Site insights

Work at this site?

Active trials

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Trial sponsors